Verastem, Inc. Files 8-K Report

Ticker: VSTM · Form: 8-K · Filed: Oct 17, 2024 · CIK: 1526119

Verastem, INC. 8-K Filing Summary
FieldDetail
CompanyVerastem, INC. (VSTM)
Form Type8-K
Filed DateOct 17, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, financials

Related Tickers: VSTM

TL;DR

Verastem (VSTM) filed an 8-K on Oct 17th covering Reg FD, other events, and financials.

AI Summary

On October 17, 2024, Verastem, Inc. filed an 8-K report detailing several key events. The filing includes information on Regulation FD disclosures, other events, and financial statements and exhibits. The company, incorporated in Delaware, is headquartered in Needham, MA.

Why It Matters

This 8-K filing provides important updates and disclosures from Verastem, Inc. to investors and the public regarding company events and financial information.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of corporate events and financial information, not indicating any immediate or significant risk.

Key Numbers

Key Players & Entities

FAQ

What specific events are disclosed under Regulation FD?

The filing indicates a Regulation FD Disclosure but does not detail the specific events within the provided text.

What is the nature of the 'Other Events' reported?

The filing lists 'Other Events' as a category but does not specify the nature of these events in the provided text.

What financial statements or exhibits are included in this filing?

The filing mentions 'Financial Statements and Exhibits' as a category but does not list the specific documents in the provided text.

When was Verastem, Inc. incorporated?

Verastem, Inc. was incorporated in Delaware.

Where are Verastem, Inc.'s principal executive offices located?

Verastem, Inc.'s principal executive offices are located at 117 Kendrick Street, Suite 500, Needham, MA 02494.

Filing Stats: 625 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2024-10-17 11:50:50

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 17, 2024, Verastem, Inc. (the "Company" or "Verastem") presented updated, mature data from the ongoing Phase 2 RAMP 201 (ENGOTov60/GOG3052) ("RAMP 201") clinical trial evaluating the combination of avutometinib, an oral RAF/MEK clamp, and defactinib, an oral, selective focal adhesion kinase (FAK) inhibitor, in patients with recurrent low-grade serous ovarian cancer at the International Gynecologic Cancer Society ("IGCS") 2024 Annual Meeting in Dublin, Ireland. The Company posted the IGCS presentation on its website, a copy of which is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K. On October 17, 2024, the Company also posted a presentation to its website, which the Company intends to use during its previously announced investor conference call and webcast to review the mature data from the RAMP 201 trial on October 17, 2024, at 4:30 p.m. Eastern Time. A copy of the presentation is furnished hereto as Exhibit 99.2 to this Current Report on Form 8-K.

01 Other Events

Item 8.01 Other Events. On October 17, 2024, the Company issued a press release announcing the mature data from the RAMP 201 trial and providing an update on the status of the associated rolling submission of a new drug application to the U.S. Food and Drug Administration. A copy of this press release is filed hereto as Exhibit 99.3 to this Current Report on Form 8-K.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits Exhibit No. Description 99.1 IGCS Presentation, dated October 17, 2024 99.2 Investor Presentation, dated October 17, 2024 99.3 Press Release, dated October 17, 2024 relating to Verastem's RAMP 201 Trial Data 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERASTEM, INC. Dated: October 17, 2024 By: /s/ Daniel W. Paterson Daniel W. Paterson President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing